Hemodialysis access: Influence of the human immunodeficiency virus on patency and infection rates  by Curi, Michael A. et al.
608
Hemodialysis access: Influence of the
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Purpose: The complication rate for patients who are dialysis dependent and infected with
the human immunodeficiency virus (HIV) and the role of viral indicators (CD4 counts)
as predictors of these complications are poorly characterized. To determine the influence
of HIV status and viral activity on graft patency and infection rates, we retrospectively
reviewed our results.
Methods: Between June 1993 and March 1997, the charts of 104 patients (HIV+, n = 42;
HIV–, n = 62) who required 112 hemodialysis access grafts were reviewed. Of the 112
procedures, 55 (48%) were autologous arteriovenous fistulae (AVF) procedures (HIV+,
n = 23; HIV–, n = 32) and 57 (52%) were prosthetic expanded polytetrafluoroethylene
grafting procedures (HIV+, n = 27; HIV–, n = 30). Transcutaneous catheter procedures
were excluded from the study. The autologous AVF procedures consisted of direct and
transposed AVFs. Patency rates were determined by means of life-table analysis.
Infection rates and CD4 counts were compared with the c 2 test and the Fisher exact test.
Significance was accepted at a P value of .05 or less.
Results: The cumulative 12-month and 24-month patency rates for prosthetic grafts in
patients who were HIV+ were 49% and 21%, respectively, versus 77% and 45% for
patients who were HIV–. The differences in the prosthetic graft patency rates between
these two groups were significant (P ≤ .05). The cumulative 12-month and 24-month
patency rates for autologous AVF procedures did not differ significantly. The AVF pro-
cedure patency rates were 72% and 51%, respectively, in patients who were HIV+ versus
54% and 50% for patients who were HIV–. The prosthetic graft infection rate for
patients who were HIV+ and HIV– were 30% and 7%, respectively (P = .04). However,
the infection rates in autologous AVF procedures did not differ between the groups (9%
vs 0%; P > .05). The mean CD4+ cell counts were 174: CD4+ counts that were less than
200 did not correlate with or predict the development of infection (P > .05). 
Conclusion: Our data showed that prosthetic graft infection rates were increased and
patency rates were decreased in patients who were HIV+ as compared with patients who
were HIV– and HIV+ with autologous AVFs. There were no differences in patency rates
or infection rates in patients who had undergone autologous access procedures. Long-
term graft patency rates were not affected by HIV status, and CD4+ lymphocyte counts
were not predictive of infection development. Because the prosthetic graft infection rates
exceeded those rates of autologous access procedures, we recommend the vigorous use
of autologous AVFs in all patients who are HIV+, regardless of CD4+ count. (J Vasc
Surg 1999;29:608-16.)
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therapy, bacteremia, or life-threatening sepsis. The
primary patency rate was determined as per the
Society for Vascular Surgery/International Society for
Cardiovascular Surgery recommendations on report-
ing standards.10 The patent grafts that could not be
used for hemodialysis (because of failure to mature)
were counted as failed or occluded grafts. 
Statistical analysis. A comparison of infection
rates was performed by means of the c 2 test and the
Fisher exact test with the computer statistical soft-
ware package Graphpad Instat (Graphpad Software,
San Diego, Calif). The cumulative primary patency
rates were determined with life-table analysis as
described by the Ad Hoc Committee on Reporting
Standards.10-12 Multivariate analysis was performed
with logistic regression analysis on the JMP statisti-
cal software package (SAS Institute Inc, Cary, NC).
Comparisons between the life-table graphs were per-
formed with the log-rank test. Statistical significance
was accepted at a P value of .05 or less.
RESULTS
Demographics. The study consisted of 104
patients (HIV+, n = 42; HIV–, n = 62) who required
112 hemodialysis access procedures. Of the 112 pro-
cedures, 55 (48%) were autologous AVF procedures
(HIV+, n = 23; HIV–, n = 32) and 57 (52%) were
prosthetic expanded polytetrafluoroethylene graft
procedures (HIV+, n = 27; HIV–, n = 30). There
were 79 men (76%) and 25 women (24%), with a
mean age of 52 years. Eighty-five patients (82%) were
black, nine (9%) were white, four (4%) were
Hispanic, and six (6%) were Asian. A history of intra-
venous drug abuse (IVDA) was observed in 55% of
the patients who were HIV+ (23 of 42) and 2% of
the patients who were HIV– (1 of 62). The route of
HIV transmission was through IVDA in 23 patients
(53%), sexual contact in 11 patients (26%), and
unknown means in eight patients (19%). The sub-
group distribution and associated comorbid condi-
tions are listed in Tables I and II. 
The following variables were analyzed: age; sex;
race; cause of HIV infection; CD4+ (cluster designa-
tion 4) T-helper lymphocyte cell counts; current
medications; associated medical conditions, such as
diabetes; systemic lupus erythematosus; history of
IVDA; vascular access procedures performed; access
complications; and mortality. 
Graft infection. Twelve infections (11%) were
reported in the 112 access procedures. Among the
autologous AVF procedures, there were two infec-
tions (9%) in the HIV+ group and no infections
(0%) in the HIV– group (P = .17). Among the pros-
With the advent of the serine protease inhibitors
and multidrug treatment regimens, patients who are
infected with the human immunodeficiency virus
(HIV) are surviving for longer periods of time.1 The
increase in long-term survival rates has been associ-
ated with similar increases in HIV-associated dis-
eases. From 1990 to 1994, the incidence rate of
HIV nephropathy that causes dialysis dependence
increased 100% in the United States.2-6
Vascular access complications constitute 15% to
48% of all hospital admissions for patients who are
HIV– and hemodialysis dependent.7,8 Diabetes mel-
litus, age, and black race have all been reported as
risk factors for graft infection and poor long-term
patency.9 However, the influence of concurrent HIV
infection on prosthetic graft and autologous arteri-
ovenous fistulae (AVF) infection and patency rates is
poorly understood and infrequently reported.
Similarly, the role of viral indicators (CD4+ T-helper
cell lymphocyte) as predictors for the development
of infectious complications is unknown. To elucidate
these issues, we retrospectively reviewed the infec-
tion and patency rates in patients who were HIV+
and dialysis dependent and compared them with
those of a cohort group of patients who were HIV–
and required hemodialysis. 
MATERIALS AND METHODS
Patient demographics. The hospital charts and
dialysis unit records of patients who required pros-
thetic and autologous hemodialysis access between
June of 1993 and March of 1997 were retrospective-
ly reviewed after Institutional Review Board approval
from University of Medicine and Dentistry of New
Jersey–New Jersey Medical School was obtained.
Patients who required Hickman (C.R. Bard, Inc,
Murray Hill, NJ) and other temporary indwelling
catheter access procedures were excluded from the
analysis. From June of 1993 to March of 1997,
hemodialysis access procedures (57 prosthetic and 55
autologous) were performed in 104 patients. Of
these patients, 42 were identified as being HIV+ and
were compared with a cohort group of 62 patients
who were HIV–. The prosthetic graft and autolo-
gous AVF infection and patency rates were deter-
mined for each group. A multifactorial analysis of
concurrent medical risk factors also was performed.
Infection and patency criteria. Grafts were con-
sidered infected when there was any sign of soft tissue
infection adjacent to the graft that necessitated intra-
venous antibiotics or graft removal for treatment.
Grafts were removed if there was gross evidence of
purulence, infection not amenable to antibacterial
thetic grafts, eight infections (30%) in the HIV+
group and two (7%) in the HIV– group occurred (P
= .04; Fig 1). The infection rates for the patients
who were HIV+ relative to the access type showed
eight prosthetic graft infections (30%) and two
autologous AVF infections (9%; P = .08). All the
prosthetic graft infections necessitated graft removal.
Autologous graft infections were treated successful-
ly with intravenous antibiotics. A history of IVDA (p
< .01) was significantly associated with the develop-
ment of a graft infection (Fig 2). Patients with a his-
tory of IVDA had a 33% graft infection rate, and
patients with no history of IVDA had a 3% graft
infection rate.
The Centers for Disease Control and Prevention
defines patients with CD4+ counts of less than 200
as having autoimmune deficiency syndrome (AIDS)
and severe immune compromise.7 Within the HIV+
group, a CD4+ lymphocyte count of less than 200
cells/m L did not correlate with an increased infec-
tion rate in the prosthetic grafts or the autologous
AVFs (Table III). Similarly, multivariate analysis of
sex, age, race, route of HIV transmission, presence
of diabetes mellitus, hypertension, or any other
comorbid conditions did not show an independent
risk factor associated with infection.
Graft patency. The 12-month and 24-month
patency rates for the prosthetic grafts were 49% and
21%, respectively, in the patients who were HIV+
(Table IV) and 77% and 45% in the patients who
were HIV– (Fig 3; Table V). The overall patency
rates between the two groups differed significantly
(P ≤ .05). The differences were most pronounced at
6 to 9 months and 18 to 24 months. The 12-month
and 24-month primary cumulative patency rates for
autologous AVFs were 72% and 51%, respectively, in
the patients who were HIV+ (Table VI) and 54%
and 50% in the patients who were HIV– (Fig 4;
Table VII). The autologous AVF patency rates did
not differ between patients who were HIV+ and
HIV–. In a comparison of the different types of
access within the HIV+ group, the 12-month and
24-month patency rates were 49% and 21%, respec-
tively, for prosthetic grafts and 72% and 51% for
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Table I. Demographics of patient population
Total no. of patients No. of patients who were HIV+ No. of patients who were HIV–
Mean age (years) 52 39 60* (P < .05)
Sex M: 79 (76%) M: 27 (64%) M: 52 (84%)
F: 25 (24%) F: 15 (36%) F: 10 (16%)
Race B: 85 (82%) B: 39 (93%) B: 46 (74%)
W: 9 (9%) W: 0 (0%) W: 9 (15%)
H: 4 (4%) H: 2 (5%) H: 2 (5%)
U: 6 (6%) U: 1 (2%) U: 5 (8%)
Type of access graft AVF: 55 (48%) AVF: 23 (46%) AVF: 32 (52%)
PG: 57 (52%) Radiocephalic: 20 Radiocephalic: 31
Unspecified AVF type: 3 Unspecified AVF type: 1
PG: 27 (54%) PG: 30 (48%)
Brach-ax: 23 Brach-ax: 16
Forearm Loop: 4 Forearm loop: 12
Unspecified site: 2
M, Male; F, female; B, black; W, white; H, Hispanic; U, unknown/other; AVF, arteriovenous fistulae; PG, prosthetic grafts; Brach-ax,
brachial artery-axillary vein bridging graft.
*Age of patients who were HIV– was significantly older as compared with patients who were HIV+.
Table II. Comorbid conditions
No. of patients who were HIV+ No. of patients who were HIV– Total no. of patients P value
Diabetes 2 (5%) 20 (32%) 22 (21%) .001
Hypertension 25 (58%) 34 (55%) 59 (57%) NS
Coronary artery disease 4 (9%) 18 (29%) 22 (21%) .03
Tobacco use 22 (52%) 8 (13%) 31 (30%) .001
History of IVDA 23 (55%) 1 (2%) 24 (23%) .001
IVDA, Intravenous drug abuse.
autologous AVFs (Fig 5). The overall patency rates
were significantly higher in the patients who were
HIV+ with autologous AVFs as compared with the
patients who were HIV+ with prosthetic bridging
grafts (P ≤ .001).
A history of IVDA had no effect on prosthetic
and autologous graft patency rates, regardless of
HIV status. Similarly, a multivariate analysis of sex,
age, race, route of HIV transmission, presence of
diabetes mellitus, hypertension, or any other comor-
bid conditions failed to show independent predic-
tors associated with decreased graft patency rates. 
DISCUSSION
During the 1990s, the rate of end stage renal dis-
ease caused by HIV nephropathy has more than
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Fig 1. Infection rates for prosthetic bridging grafts in
patients who were HIV+ versus HIV– show increased
infection rates in patients who were HIV+.
Fig 2. Incidence rates of graft infection as a function of
intravenous drug abuse history.
Table IV. Primary cumulative patency rates of prosthetic grafts in patients who were HIV+
No. of patients No. of No. lost No. of Interval Cumulative 
Interval (months) at risk failed grafts Duration to follow-up deaths patency rate patency rate SE
0 to 1 27 3 0 0 0 0.89 100% 0
1 to 3 24 4 0 0 0 0.83 89% 6
3 to 6 20 3 0 1 1 0.83 74% 8.4
6 to 9 15 3 0 0 0 0.8 62% 9.9
9 to 12 12 1 0 0 0 0.92 49% 10.1
12 to 15 11 2 0 0 0 0.82 45% 10.1
15 to 18 9 2 0 0 0 0.78 37% 9.8
18 to 21 7 2 0 0 0 0.71 29% 11.2
21 to 24 5 1 0 0 0 0.8 21% 11.2
SE, Standard error.
Table III. Infection rates and CD4+ lymphocyte counts
<50 <100 <200 >200 Significance
Prosthetic infection rate (%) 50 29 30 25 P > .05
Autologous infection rate (%) 17 10 7 10 P > .05
doubled.2-6 Inner-city dialysis units have reported
the incidence rate of HIV seropositivity to range
from 12% to 23%, with most patients reporting a his-
tory of IVDA.13-15 These patients are considered to
be at a high risk for the development of access-relat-
ed complications and septic deaths from prosthetic
graft infections. The clinical significance of HIV
seropositivity and the role of viral indicators in
assessing infection and patency rates in this growing
patient population is poorly delineated.
Complications associated with dialysis access are
a common cause for hospital admissions in patients
who are HIV– and dialysis dependent and, in one
series, accounted for 48% of the hospitalizations.7
To decrease the incidence rate of access-related com-
plications, increased use of peritoneal dialysis
catheter and autogenous AVFs has been recom-
mended. Autogenous AVFs have 30% to 50% fewer
complications and better long-term patency rates
than do prosthetic bridging grafts but constitute
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Fig 3. Cumulative primary patency rates of prosthetic grafts in patients who were HIV+ versus HIV–.
Prosthetic graft patency rates in patients who were HIV– were significantly higher than in patients who
were HIV+ (P ≤.05).
Fig 4. Cumulative primary patency rates of autologous arteriovenous fistulae in patients who were
HIV+ versus HIV–. Differences in patency rates between the two groups were not significant.
only 16.5% of the access grafts placed in the United
States today.7,16-18 Prosthetic bridging grafts are the
most common access procedures performed and
have the highest complication rates.8,17-25 In
patients who are HIV–, the prosthetic graft infection
rates have been reported to range from 9% to 15%,
with primary patency rates as low as 41% and 24% at
1 and 2 years, respectively.9,18-25 In the current
series, prosthetic bridging grafts in patients who
were HIV+ had poorer short-term and long-term
patency rates as compared with patients who were
HIV– (P ≤ .05; Fig 3). No differences in patency
rates between the patients who were HIV+ and
HIV– with autologous AVFs were observed.
However, a significant increase in graft patency rates
was observed in the patients who were HIV+ with
AVFs as compared with the patients who were HIV+
with bridging grafts (P ≤ .001).
In the current series, the patients who were HIV+
with prosthetic bridging grafts had a significantly
increased infection rate (8 of 27; 30%) as compared
with the patients who were HIV– with prosthetic
bridging grafts (2 of 30; 7%; P = .04). This increase
in the prosthetic graft infection rate is consistent with
that observed by Brock et al.15 In this series, the
authors reported prosthetic graft infection rates of
43%, 36%, and 41% in patients with AIDS, patients
who were HIV+ without AIDS, and patients with a
history of IVDA, respectively. Prosthetic bridging
grafts in patients who were HIV+ showed a trend
towards higher infection rates as compared with
autologous AVFs in the same group (2 of 23; 9%; P
= .08). Infection rates for AVFs in the patients who
were HIV+ did not differ as compared with the
patients who were HIV– (9% vs 0%; P = .17). In the
series reported by Brock et al,15 prosthetic graft
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Fig 5. Cumulative primary patency rates of autologous arteriovenous fistulae versus prosthetic grafts in
patients who were HIV+. Patency rates between arteriovenous fistulae and prosthetic bridging grafts dif-
fered significantly (P ≤ .001).
Table V. Primary cumulative patency rates of prosthetic grafts in patients who were HIV– 
No. of patients No. of No. lost to No. of Interval Cumulative
Interval (months) at risk failed grafts Duration follow-up deaths patency rate patency rate SE
0 to 1 30 0 0 0 0 1 100% 0
1 to 3 30 2 0 0 0 0.93 100% 0
3 to 6 28 4 0 0 0 0.86 93% 4.6
6 to 9 24 1 0 0 0 0.96 80% 7.3
9 to 12 23 3 2 0 0 0.86 77% 7.7
12 to 15 18 4 1 0 0 0.76 66% 9.1
15 to 18 13 0 1 1 1 1 50% 9.8
18 to 21 10 1 0 0 0 0.9 50% 11.2
21 to 24 9 0 0 0 0 1 45% 11.2
SE, Standard error.
infections resulted in 23 of 25 grafts that necessitat-
ed excision and none of the autogenous AVFs devel-
oped an infection. In the current series, the two
infected autologous AVFs were treated successfully
with intravenous antibiotics alone, and eight of eight
prosthetic grafts necessitated excision. 
CD4+ lymphocyte cell counts have been shown
to clinically correlate with deteriorating or improv-
ing immune status in patients with AIDS and HIV.26
To determine whether or not T-helper cell levels
predisposed patients who were HIV+ and undergo-
ing hemodialysis to an increased rate of infection, we
compared the infection rates of patients who were
HIV+ with CD4+ counts greater than and less than
200. We chose a level of 200 cells/ m L because
patients with CD4+ counts of less than 200 are con-
sidered to have AIDS and severe immune compro-
mise.26 However, the results from the current series
failed to show a correlation between increased pros-
thetic graft or autologous AVF infections and
decreased CD4+ lymphocyte cell counts. CD4+
counts, therefore, do not appear to predict the rates
of infection in patients who were HIV+ and are
undergoing hemodialysis access procedures.
Because of the increased infection rates with
prosthetic grafts in patients who are HIV+, we rec-
ommend avoiding prosthetic graft material and
using autologous AVFs. The implementation of this
practice policy, however, is difficult because of the
high percentage of patients who are HIV+ with a
history of IVDA. These patients frequently use
tourniquet compression to identify veins for intra-
venous injections. Eventually, these veins become
phlebitic, nondistensible, and unavailable for use in
hemodialysis procedures. Consequently, prosthetic
grafts are placed commonly in these patients using
deeper lying, uninjured veins. In an effort to
increase the use of autologous access procedures,
even in the IVDA population, the authors use
duplex ultrasound scanning, rather than clinical
examination alone, to assess the suitability of upper
extremity veins.27,28 Since initiating this protocol,
our analysis has shown that 53% of the patients who
underwent autologous AVF procedures were not
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Table VI. Primary cumulative patency rates of autologous fistulae in patients who were HIV+
No. of patients No. of No. lost to No. of Interval Cumulative
Interval (months) at risk failed grafts Duration follow-up deaths patency rate patency rate SE
0 to 1 23 0 0 0 0 1 100% 0
1 to 3 23 5 0 0 1 0.77 100% 0
3 to 6 17 0 0 0 0 1 77% 8.9
6 to 9 17 1 1 0 1 0.93 77% 8.9
9 to 12 14 0 1 0 2 1 72% 10.2
12 to 15 11 1 0 0 0 0.91 72% 11.5
15 to 18 10 0 0 0 0 1 66% 12.2
18 to 21 10 2 1 0 0 0.78 66% 12.2
21 to 24 7 0 1 0 0 1 51% 13.5
SE, Standard error.
Table VII. Primary cumulative patency rates of autologous fistulae in patients who were HIV–
No. of patients No. of No. lost to No. of Interval Cumulative
Interval (months) at risk failed grafts Duration follow-up deaths patency rate patency rate SE
0 to 1 32 2 0 0 0 0.94 100% 0
1 to 3 30 6 0 0 0 0.8 94% 4.3
3 to 6 24 4 1 0 0 0.83 75% 7.7
6 to 9 19 2 3 0 0 0.88 62% 8.8
9 to 12 14 0 2 0 0 1 54% 9.8
12 to 15 12 0 0 0 0 1 54% 10.6
15 to 18 12 1 0 0 0 0.92 54% 10.6
18 to 21 11 0 1 0 0 1 50% 10.6
21 to 24 10 0 1 0 0 1 50% 11.1
SE, Standard error.
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candidates on the basis of clinical examination
alone.28 In addition, our use of autogenous AVFs
has increased from 14% to 63% and our prosthetic
graft use has decreased from 62% to 30%.28 In the
current series, the patency rates for autologous AVFs
in patients who were HIV+ were superior to the
rates for prosthetic grafts and similar to the rates for
autologous AVFs placed in patients who were HIV–.
We therefore recommend preoperative assessment of
upper extremity veins in all patients who require
hemodialysis. In the patients who are HIV+ and at a
higher risk, the use of prosthetic grafts should be
avoided if possible.
CONCLUSION
Our data show increased infection rates and
decreased patency rates in patients who are HIV+ and
require prosthetic hemodialysis access grafts.
Infection and patency rates for autologous AVFs were
similar in patients who were HIV+ and HIV–.
Furthermore, CD4+ lymphocyte cell counts did not
predict the development of graft infections in patients
who were HIV+. On the basis of these data, we rec-
ommend avoidance of prosthetic grafts for hemodial-
ysis access in patients who are HIV+. Clinical exami-
nation alone inadequately assesses the patients for
autologous AVFs. By using duplex ultrasound scan-
ning to assess the suitability of upper extremity veins,
the use of autologous AVFs can be increased in all
patients and especially those with HIV infection.
We thank Dr Joan Skurnick, PhD, Assistant Professor,
Department of Pediatrics, Division of Preventative
Medicine, for her help in analyzing the data.
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